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Background: Diabetic Macular Edema (DME) is a common cause of impaired vision and blindness amongst
diabetics. If not detected and treated early, the resulting vision loss can lead to considerable health costs and
decreased health-related quality of life (HRQoL). The aim of this study was to provide evidence of the psychometric
properties of the National Eye Institute - Visual Functioning Questionnaire (VFQ-25) for use in a cohort of DME
patients who participated in a clinical efficacy and safety trial of pegaptinib sodium (Macugen).
Methods: A phase 2/3 randomised, double masked trial evaluated pegaptanib injection versus sham injection in
patients with DME. The analysis was conducted using baseline HRQoL data of the VFQ-25 and the EQ-5D, on a
modified intent-to-treat sample of 235 patients. These measures were administered by a trained interviewer by
telephone in all but one of the study countries, where face-to-face interviews were conducted in the clinic. The
measures were completed in the week prior to baseline, and after 54 weeks of treatment. Distance visual acuity,
measured according to the Early Treatment Diabetic Retinopathy Study (ETDRS), was assessed at all time points.
Psychometric properties of the VFQ-25 assessed included domain structure, reliability, concurrent and construct
validity, responsiveness.
Results: The VFQ-25 was found to consist of 11 domains slightly different than those proposed. Nevertheless, none
of the eight established multi-item scales met the criterion for further splitting and the VFQ-25 was scored as in the
developers’ instructions. Internal consistency reliability was demonstrated for six out of the eight original multi-item
scales, with Cronbach's alpha ranging from 0.58 (Distance Activities) to 0.85 (Vision Specific: Dependency). The
VFQ-25 domains generally showed a low to moderate correlation with EQ-5D visual analogue scale (range 0.16-0.43)
and with the visual acuity score (range 0.10-0.41). Construct validity was upheld with higher VFQ-25 scores for patients
who saw more letters according to the ETDRS. Almost all scales were shown to be responsive with Guyatt's statistic
ranging from 0.10 to 0.56 at 54 weeks.
Conclusions: The VFQ-25 has evidence to support its validity and reliability for measuring HRQoL in DME. However,
some operating characteristics of the instrument need further consideration and discussion in the case of DME
patients. Further research is therefore warranted in this indication.
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Diabetic macular edema (DME) is one of the most com-
mon causes of impaired vision and blindness amongst
diabetic patients [1]. DME is the result of long-term ex-
cess blood-glucose on the microvascular system of the
eye. Over time, this leads to diabetic retinopathy, and in
some patients results in edema of the macula (the cone-
rich centre of the retina responsible for day-time colour
vision). The Early Treatment Diabetic Retinopathy Study
(ETDRS), a pivotal study in DME, defined macular
edema as thickening of the retina and/or hard exudates
within one disc diameter of the centre of the macula [2].
The standard of care to treat DME is focal/grid laser
photocoagulation; however, earlier in 2011 intravitral in-
jection of an anti-vascular endothelial growth factor,
ranibizumab, was approved for the treatment of DME,
and further treatments are in development.
In addition to visual improvement, it is important to
measure efficacy of DME treatment which is evaluated
in terms of the impact on patients’ ability to function
and complete their usual activities. Measures of vision-
related or health-related quality of life (HRQoL) have
been developed to assess the broader impact of poor vis-
ual functioning [3,4]. Generic measures such as the EQ-
5D also exist which are designed to be valid assessments
of HRQoL in any disease area [5].
Decreasing vision has a complex relationship with
HRQoL; in addition to the impact on people’s ability to
complete their usual daily activities, the loss of visual
function combined with the threat of further declines in
visual function may affect psychological state or lead to
social isolation [6]. There are several condition-specific
measures or instruments which are designed to capture
the specific impact of vision loss on HRQoL. The
National Eye Institute in collaboration with RAND devel-
oped the Visual Function Questionnaire (VFQ-25), which
is probably the most widely used and researched HRQoL
measure in this field. The VFQ-25 is a vision-specific
measure of HRQoL composed of eight multi-item scales,
four single-item scales, and one composite score ranging
in value from 0 (poor) to 100 (high HRQoL). The follow-
ing dimensions of vision-targeted function and HRQoL
comprise the VFQ-25: overall vision, difficulty with near
vision activities, difficulty with distance vision activities,
limitations in social functioning due to vision, role limita-
tions due to vision, dependency on others due to vision,
mental health symptoms due to vision, driving difficulties,
limitations with peripheral and colour vision, and ocular
pain. The measure provides an algorithm to calculate a
composite score based on the subscales, and additionally
contains one item for subject rating of general health
status.
The development and psychometric characteristics of
the VFQ-25 have been documented [7,8]. The VFQ-25has been developed to be appropriate to use across a
range of visual disorders and to measure their effects.
This is an advantage over other measures which are
more specific such as the VF-14 [4] which was devel-
oped to assess outcomes associated with cataracts and
associated treatments. The VFQ-25 has been used in a
wide range of different ophthalmology indications [9].
The Los Angeles Latino Eye Study (LALES) is one
prominent example where the impact of vision loss on
HRQoL was assessed over four years in a population co-
hort. The study assessed different conditions including
glaucoma, retinopathy and age-related macular degener-
ation. This work revealed the domains of the VFQ-25,
such as vision-related mental health, which were most
sensitive to loss of vision. Mazhar et al. [10] present
more LALES data which focussed on the changes in
HRQoL experienced by people with diabetic retinopathy.
Existing evidence regarding the VFQ-25 in other indi-
cations suggests that it possesses good internal
consistency reliability, and correlates well overall with
visual acuity (measured in terms of ETDRS) [7,8]. Des-
pite the widespread use of the VFQ-25, the evidence of
validity of the VFQ-25 in people with DME is sparse and
needs further elucidation. Psychometric validation of
instruments should always be considered as an on-going
process [11], and the validity of an instrument can never
be assumed just because it has been demonstrated in a
related area. Therefore it is very important to measure
and establish the psychometric properties of an instru-
ment when used in a new indication. This is standard
practice in outcomes research and is the expectation of
regulatory bodies and decision makers [11]. Vision disor-
ders in diabetes are known to affect HRQoL [12]. Lloyd
et al., 2008 [13], and Cusick et al. (2005) [6] show evi-
dence regarding how edema exerts an additional burden
on HRQoL. As the psychometric properties of the VFQ-25
have not been documented in this patient group, the
present study is designed to test the psychometric proper-
ties of the VFQ-25 in an adult DME population using data




The data from this trial included patients who were ran-
domised to either intravitreous (IVT) pegaptanib or
sham treatment [14,15]. In brief, the pivotal study was
a multicenter, randomized, sham-controlled, double-
masked, parallel-group, comparative trial to confirm the
safety and efficacy of pegaptanib sodium 0.3 mg, when
given as IVT injections versus sham injections. Only one
eye per patient was treated and this could be either the
worse or better eye, depending on the decision of the
treating physician. At Week 18, both arms of the trial
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discretion of the investigator according to ETDRS cri-
teria. Subsequently patients could receive focal/grid laser
photocoagulation, provided that a minimum of 17 weeks
had elapsed between treatments. Patients could not re-
ceive more than three focal/grid photocoagulations per
year. The primary efficacy endpoint in the trial was the
proportion of patients who experienced a greater than
or equal to ten letter (or 2 line) improvement in vision
(ETDRS) from baseline at 1 year.
Patients were enrolled at sites around the world includ-
ing Australia, Canada, Europe, India, South Africa and
South America. The sample used for the psychometric
analyses included the modified intention to treat Year 1
(MITT1) population which included all randomized sub-
jects who received at least one dose of study medication,
who completed the baseline visual acuity assessment, and
who had at least one post-baseline visual acuity assess-
ment by Week 54. In addition to the VFQ-25, the EQ-5D
questionnaire was administered to patients at Baseline,
Week 18, Year 1, Year 2, and also to any early withdrawals.
The study results from the HRQoL assessments have been
reported elsewhere [15].Measures
The validated and translated interview versions of the
VFQ-25 were administered to patients in this study.
Trained, certified call centre operatives telephoned all
patients in their homes and administered the question-
naires in the patient’s native language. The exception to
this was the centres in India, whereby the questionnaires
were completed face-to-face in an interview setting at
the clinic. This was necessary because there was a lack
of available speakers of the required five Indian lan-
guages at the call centre, and there was difficulty in en-
suring all patients had telephone access. Prior to
randomization, all patients were supplied with the pa-
tient brochures and interview guides to assist them with
completing the study questionnaires. This included the
instructions and the response categories as a reference
to use during the interview if they preferred. Standard
scoring procedures were used [8].
The EQ-5D is a generic preference weighted HRQoL
measure often used to support the estimation of quality-
adjusted life years for use in Health Technology Assess-
ments. It assesses health status in five domains (mobility,
self-care, usual activities, pain/discomfort and anxiety/
depression) that are transformed to a single index score,
and also includes a visual analogue scale (VAS) for self-
rated health status [5,16]. Only the EQ-5D VAS was
used for analyses in this study. Scores for the VAS range
from 0–100 where 100 represents the best imaginable
health, and 0 represents worst imaginable health.Analyses
Analyses were conducted on the MITT1 sample, using
both baseline and 54-week data. All analyses were
conducted irrespective of the assignment to treatment
arm (i.e. on masked data). All analyses were described in a
statistical analysis plan (SAP) which was finalised prior to
initiating any analysis. The psychometric properties of the
VFQ-25 were evaluated using standard tests and criteria
[11,17,18]. These included an examination of item and
scale variability, domain structure, internal consistency re-
liability, item-total correlation, concurrent validity, con-
struct validity, responsiveness, and an estimate of MID.
The level of missing data and the frequency of floor effects
(number of respondents with the lowest possible score)
and ceiling effects (number of respondents with the high-
est possible score) were also reviewed for items and scales.
All analyses were conducted in SAS Version 9.1.3 for
Windows and the SAS code was independently reviewed.
Conceptual framework
The relationship between items and domains in the
questionnaire, referred to as the conceptual framework,
was explored using principal components analysis. Prin-
cipal components analysis attempts to reduce the items
(questions) into a number of smaller components and
was undertaken here to determine whether the items
loaded into the pattern that was hypothesised by the in-
strument developers. Models were attempted which used
the eigenvalue >1 as one selection criteria. In addition
alternative models were also developed which forced
certain factor solutions. Orthogonal (varimax) and ob-
lique (promax) rotations were applied in an attempt to
provide a model that best described the data, and vari-
able (item) clustering methods were used to confirm the
scale structure and test the robustness of the resulting
multi-item scales [19]. Variable cluster analysis is a form
of factor analysis that offers interpretative advantages by
identifying groups of variables (items) that are as corre-
lated to each other among themselves and uncorrelated
to other groups as possible [20]; it was undertaken by in-
putting a polychoric correlation matrix into SAS PROC
VARCLUS, with each item group (cluster) being split
into two dimensions until each remaining cluster had a
second eigenvalue of less than one [19].
Reliability
Reliability is the extent to which a scale score is asso-
ciated with random error. It is evaluated to ensure that
the measure produces stable and internally consistent
scores. Internal consistency and reliability was measured
by Cronbach’s α [21], which identifies the degree to
which items within a scale correlate with each other to
constitute a multi-item scale. An α coefficient ≥0.70 is
considered acceptable [22]. Based on the available trial
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reliability.
Item - total (score) correlations indicate the degree of
homogeneity within a scale. Items are expected to cor-
relate more highly with their domain score than with
any other domain score [17,23]. Item-total correlation
was evaluated using the Pearson correlation coefficient.
It was not possible to estimate this metric for subscales
on the VFQ-25 with only one item (e.g. colour vision).
Despite this, the SAP stated that items should correlate
more highly with the domain score than other domains
or sub-scale scores [23].
Validity
Concurrent validity was assessed by comparing subscale
scores of the VFQ-25 with the EQ-5D VAS score (the
only other self-assessed rating of HRQoL in the study).
The other single index score from the EQ-5D, which is
based on five dimensions of health, was not included in
the concurrent validity partly because the scores are pre-
ference weighted, and because of evidence that the EQ-
5D single index score has been shown to be insensitive
to visual impairment [24].
It is difficult to make firm predictions regarding the
nature of the relationship between VFQ-25 and EQ-5D
VAS because they are not conceptually measuring the
same thing. The VFQ-25 is a disease specific measure of
HRQoL which focuses heavily on the impact of visual
impairment. The EQ-5D VAS is a measure of self-rated
health which reflects a totally subjective assessment of
the quality of their current health state and is subject to
many influences beyond vision. Therefore, there are a
priori reasons to believe that the degree of association
between these measures will be moderate at best. It was
hypothesised therefore in the SAP that correlation coef-
ficients between EQ-5D VAS and VFQ-25 domain scores
may not be much greater than 0.30. Total number of let-
ters (on ETDRS) of the patient’s visual acuity at 4 m and
1 m were also included as quasi-continuous variables in
the correlation analyses of concurrent validity. Correla-
tions with both the study eye and the fellow eye were
estimated because patients’ self-report of their HRQoL
and how their visual function affects them will be
affected by both eyes. Previous research has shown that
HRQoL can improve, regardless of whether the treated
eye is better or worse than the seeing eye [25,26].
Construct validity, whether the items/domains con-
form to what is predicted by the conceptual framework,
was measured using both discriminant (known groups)
and convergent (strength of association) approaches.
Known groups validity was assessed by comparing scores
of groups of patients defined in terms of ETDRS visual
acuity with analysis of variance and additional post hoc
tests (Tukey’s test). Convergent validity was assessedusing correlation and multiple regression analyses to ex-
plore the relationship between VFQ-25 and other
disease-related variables. Data were analysed by calculat-
ing correlation coefficients between VFQ-25 domain
scores and ETDRS scores and by fitting step-wise mul-
tiple linear regression models to determine the predic-
tors of VFQ-25 domain scores. The models included
vision-related factors: ETDRS visual acuity and duration
of vision problems, diabetes-related variables (including
measurement of glycated haemoglobin (HbA1c) and pres-
ence of other diabetic complications), and background
characteristics such as age and sex, Eastern Cooperative
Oncology Group (ECOG) status, and smoking status. It
was predicted that the VFQ-25 will be statistically asso-
ciated with both vision specific-variables and diabetes-
related variables.
Sensitivity
Sensitivity to change, or responsiveness, is the ability of an
instrument to reflect objective changes in a population.
Sensitivity was assessed in terms of changes reported by
those patients with at least a five letter improvement in
visual acuity. In many studies, a clinically relevant im-
provement is defined as ten letters at one year. The use of
five letters in the present analysis was used as a stricter
test and has been used as a benchmark in other recent re-
search [27]. Additionally, the use of five letters as the cri-
terion meant that data were available from more patients
to test sensitivity. Among patients with a ≥5 letter im-
provement in the study eye between baseline and week 54,
sensitivity of the VFQ-25 was evaluated in terms of effect
size [28], standardized response mean [29], Guyatt’s re-
sponsiveness statistic [30], and the significance of the
mean change from baseline to week 54 assessed by the
one-sample t-test. The effect size is the mean change score
divided by the SD of the baseline score. An interpretation
of effect size in the context of analysis of variance has
been provided in terms of benchmarks where 0.1 is a
small effect, 0.25 is a medium effect and 0.4 is a large ef-
fect [31]. The standardized response mean is the mean
change score divided by the SD of the change score.
Guyatt’s responsiveness statistic is the mean change score
divided by the SD of the change in subjects who remained
stable as defined by an increase or decrease of only up to
1 letter. A Guyatt’s statistic of > .20 is considered accept-
able. Change over time was compared for those who
showed a response to treatment.
Minimal important difference
MID is used to interpret whether the observed change is
important from a patient’s perspective. The MID of the
VFQ-25 was assessed using two distribution based
approaches [30,32]. The first is a one standard error of
measurement (SEM) to reflect a MID in individual patient
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line to week 54 and the test psychometric reliability (esti-
mated as a SD x square root of (1- reliability score)). A
confidence interval (CI) can be calculated around a test
score using the SEM to indicate the smallest amount of
change that would be expected to occur in the individual
with the appropriate degree of confidence/probability.
This interval is often termed the minimal detectable
change (MDC), which for a 95% CI would be an MDC95.
Pickard et al. has estimated the MID on the EQ-5D VAS
to be 7 [33]. The degree of change between baseline and
year 1 on all subscales of the VFQ-25 was estimated for
patients who report a change of 7 on EQ-5D VAS. No for-
mal assessments of self-reported change or ‘anchor ques-
tions’ specific to the domains of the VFQ-25 were available
for assessing MID.
Results
From this analysis cohort of 260 patients, 235 had non-
missing VFQ-25 baseline data and were included in the
psychometric validation (Figure 1). Table 1 shows the
background characteristics of the study group. The mean
± SD age of the analysis cohort was 62 ± 10 years, 43%
were female, and 82% were Caucasian. At baseline the ma-
jority of the patients (68%) had visual acuity in the study
eye of 69 to 55 ETDRS letters (20/50 to 20/80). Data are
also presented for patients in terms of better eye and
worse eye visual acuity.
With regard to item and scale variability, patients used
the entire range of responses for all of the VFQ-25 items. In
addition, the completion rate for all items on the VFQ-25
was 96% [26,34]. The distribution of the VFQ-25 data by
scale at baseline and at week 54 is presented in Table 2.
The VFQ-25 composite score at baseline was 66.8 ± 18.6.
The smallest and largest means were found for General
Health (40.2 ± 22.2) and Colour Vision (87.1 ± 21.2). Scores
were slightly higher at week 54 on the majority of domains,Study Group:
MITT1 cohort with non-missing baseline PR
n = 235
Mis
Modified Intent to Treat 1 (MITT1) cohort in Pfize
N = 260




Figure 1 CONSORT diagram.although direct comparisons cannot be made between
baseline and week 54 scores because the baseline cohort
was not restricted to those with follow-up data.
Domain structure
Initial principal components analysis with varimax rota-
tion identified a simple five factor solution (data not
shown). The item loadings on the newly defined factors
from the baseline dataset showed a reasonable consistency
when one looked at the vision functioning and psycho-
social components of the instrument, but less consistency
when one looked at specific factors. In a forced 11 factor
model (excluding General Health) using a varimax rota-
tion, there was no significant item loading on the 11th fac-
tor. Of the remaining ten factors, three contained only
one item and these showed a tendency to be part of other
factors. Of the seven primary factors, one factor included
seven of the 11 items from the psychosocial component of
the original scales (i.e. mental health, social and role func-
tioning, and dependency); the role difficulty scale (items
17 and 18) created its own factor in the same way as the
original factor structure. The items in the vision function-
ing domains did not load identically. Of the 11 items in
the original model, all but the colour vision item appeared
to be represented, though not in the exact six domains.
The findings for the analyses based on non-orthogonal
rotations produced very similar patterns and so are not
reported in detail here. Variable/item clustering method-
ology showed that none of the eight established multi-
item scales met the criterion for further splitting.
Reliability
Internal consistency reliability was demonstrated for six out
of the eight VFQ-25 multi-item scales, with Cronbach's
alpha ranging from 0.58 (Distance Activities) to 0.85
(Vision Specific: Dependency) (Table 3). The VFQ-25 com-
posite score showed a Cronbach’s alpha of 0.92 at baseline.O questionnaire
sing baseline PRO questionnaire: n = 25
r Protocol EOP1013H
 week 54 PRO 
sing week 54 PRO questionnaire: n = 38
Table 1 Background characteristics of study group
Characteristic Baseline (week 0) N = 235
Age (years)
Mean ± SD 62 ± 10
Median (IQR) 62 (56 – 69)
Range 20 – 83




Other (Black, Hispanic/Latino, unspecified) 18 (7.6)
ECOG Performance Status
Mean ± SD 0.5 ± 0.5
Median (IQR) 0 (0 – 1)
Range 0 – 2
Type II diabetes, n (%) 218 (92.8)
Duration of vision problems, n (%)
None 1 (0.4)
<1 year 93 (39.6)
1-5 years 122 (51.9)
6-10 years 15 (6.4)
>11 years 4 (1.7)
ETDRS visual acuity scale: study eye
85 letters or more (20/16 or more) 0 (0.0)
85-75 letters (20/20 - 20/32) 0 (0.0)
74-70 letters (20/40) 3 (1.3)
69-55 letters (20/50 - 20/80) 160 (68.1)
54-40 letters (20/100 - 20/160) 61 (26.0)
39-35 letters (20/200) 11 (4.7)
34 letters or less (20/250 or less) 0 (0.0)
ETDRS visual acuity scale: fellow eye
85 letters or more (20/16 or more) 11 (4.7)
85-75 letters (20/20 - 20/32) 75 (32.2)
74-70 letters (20/40) 30 (12.9)
69-55 letters (20/50 - 20/80) 60 (25.8)
54-40 letters (20/100 - 20/160) 31 (13.3)
39-35 letters (20/200) 9 (3.9)
34 letters or less (20/250 or less) 14 (6.0)
Counting fingers-hand motion 3 (1.3)
* ETDRS = Early Treatment Diabetic Retinopathy Study.
Note: Percentages are based on non-missing categories.
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multi-item scale with the exception of Distance Activities
and Social Functioning (0.64). It should be noted though
that these two domains are based on just two items and so
this will naturally limit any estimates of Cronbach’s alpha.Validity
Concurrent validity findings were mixed (Table 3). The
VFQ-25 domains generally showed a low-to-moderate
correlation with the EQ-5D VAS (range 0.16 – 0.43).
There were particularly low correlations between EQ-5D
VAS and Role Difficulties, Colour Vision, Peripheral
Vision, and Ocular Pain. The slightly higher correlations
(compared with the correlations with visual acuity) suggest
that the VFQ-25 may be measuring HRQoL in a quite
generic way.
Known groups validity was upheld with higher VFQ-25
scores for patients who saw more ETDRS letters. The
mean VFQ-25 composite score was significantly higher
when comparing the quartile of patients with the best vi-
sion to the quartile of patients with the worst vision (based
on ETDRS visual acuity score) (72.1 ± 17.9 and 56.1 ± 18.0,
respectively, P value < .001). With the exception of Ocular
Pain and Colour Vision (P value = 0.52 and 0.14, respect-
ively), all other results were statistically significant
(Table 3).
Convergent validity findings were mixed. The domains
overall showed low to moderate correlations with ETDRS
visual acuity score for the study eye (range 0.10 – 0.41), and
for the fellow eye (range 0.01 – 0.51). The domains of Role
Difficulties, Colour Vision, Peripheral Vision, and Ocular
Pain correlated poorly (<0.3) with the ETDRS visual acuity
score. Convergent validity was further explored through
multiple regression analyses (data not shown). Using step-
wise selection, it was found that the ETDRS visual acuity,
EQ-5D VAS, HbA1c, age, gender, ECOG and duration of
vision problems were all predictors of different VFQ-25 do-
main scores (Table 4). EQ-5D VAS and ETDRS were the
most consistent predictors of VFQ scores. These results
also suggested that the VFQ-25 may be measuring HRQoL
in a quite generic way, capturing many aspects of general
health status rather than purely vision specific information.Sensitivity
The data in Table 5 show the sensitivity to change of the
instrument in patients who reported a ≥5 gain from
baseline to Week 54. The mean change varied from 0.54
(Social Functioning) to 11.29 (Role Difficulties), with an
overall change of 4.90 for the VFQ-25 composite score
(P value < .001). However, only General Vision, Near
Activities, Mental Health, Role Difficulties, and Driving
showed statistically significant differences assessed by the
one-sample t-test.
There was also a degree of variation between the dimen-
sions in terms of different statistical approaches. However,
consistent with the mean change score, the same scales
were shown to be responsive (except for Social Function-
ing) in terms of estimates of effect size, standardized re-
sponse mean, and Guyatt's statistic at 54 weeks.
Table 2 Distribution of scale scores
Questionnaire and Domain Question number(s) Baseline (week 0) N = 235 Follow-up (week 54) N = 197
Mean ± SD Median (IQR) Mean ± SD Median (IQR)
VFQ-25: Empirical range is 0 to 100 where a
higher score indicates better HRQoL
1. General Health 1 40.2 ± 22.2 50.0 (25.0-50.0) 40.9 ± 21.0 50.0 (25.0-50.0)
2. General Vision 2 54.6 ± 17.8 60.0 (40.0-60.0) 62.2 ± 15.4 60.0 (60.0-80.0)
3. Ocular Pain 4, 19 78.8 ± 22.3 87.5 (62.5-100.0) 82.2 ± 19.7 87.5 (62.5-100.0)
4. Near Activities 5, 6, 7 58.6 ± 23.8 58.3 (33.3-75.0) 61.0 ± 23.9 58.3 (41.7-83.3)
5. Distance Activities 8, 9, 14 64.2 ± 24.4 66.7 (41.7-83.3) 66.1 ± 25.6 66.7 (50.0-91.7)
6. Social Functioning 11, 13 80.1 ± 23.1 87.5 (62.5-100.0) 78.6 ± 23.2 87.5 (62.5-100.0)
7. Mental Health 3, 21, 22, 25 58.2 ± 27.7 62.5 (37.5-81.3) 64.2 ± 25.2 68.8 (50.0-87.5)
8. Role Difficulties 17, 18 54.8 ± 28.0 50.0 (37.5-75.0) 61.7 ± 27.8 62.5 (37.5-87.5)
9. Dependence 20, 23, 24 70.1 ± 31.2 83.3 (41.7-100.0) 73.7 ± 28.2 83.3 (58.3-100.0)
10. Driving* 15c, 16, 16a 51.8 ± 34.9 58.3 (16.7-83.3) 53.9 ± 35.6 66.7 (16.7-83.3)
11. Colour Vision 12 87.1 ± 21.2 100.0 (75.0-100.0) 87.2 ± 21.5 100.0 (75.0-100.0)
12. Peripheral Vision 10 71.3 ± 25.8 75.0 (50.0-100.0) 74.6 ± 25.4 75.0 (50.0-100.0)
VFQ-25 Composite 1-14, 15c, 16, 16a, 17-25 66.8 ± 18.6 68.8 (53.5-82.8) 70.1 ± 18.7 71.5 (57.2-86.6)
EQ-5D VAS: Empirical range is 0 to 100 where a
higher score indicates better health
65.7 ± 16.8 70 (50-80) 67.3 ± 17.0 70 (60-80)
EQ-5D single index 0.748 ± 0.203 0.779 (0.689-0.848) 0.727 ± 0.238 0.727 (0.689-0.850)
Note: Direct comparison between baseline and follow-up data should not be made because the baseline cohort was not restricted to those who also have
follow-up data.
* Some patients are no longer currently driving, leading to higher amount of missingness in this subscale: N = 151 at baseline and N = 122 at week 54.
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Table 6 provides estimates of MID using a distribution
approach. MID ranged from 8.80 (General Vision) to
14.40 (Role Difficulties) with an overall 6.13 points for the
VFQ-25 composite score using ½ SD distribution based
methods. SEM was available for eight out of 11 dimen-
sions, due to the requirement of needing Cronbach’s alpha
in the calculation. SEM showed similar results ranging
from 8.79 (Driving) to 14.04 (Role Difficulties), with a
lower estimate for the VFQ-25 composite score (3.33).
Discussion
The analyses of the domain structures of the VFQ-25 do
not perfectly describe the proposed structure of the in-
strument. The analyses provided support for the concep-
tual model but there were also some differences of note.
The ‘worry’ item (Q 3) did not load onto the mental
health domain in the new model, but instead became a
separate and distinct single item factor. The general
driving question was associated with social functioning
whereas the driving in difficult conditions or at night
items both fell out as a separate domain. The social
functioning domain seemed to disappear with both
items being redistributed to other domains. The near vi-
sion item which refers to seeing things on a crowded
shelf was aligned with the distance vision domain asopposed to the near vision domain of the original model.
The results were similar when using baseline data alone
and when pooling baseline and follow-up data at Week
54. However, variable clustering methodology showed
that none of the eight established multi-item scales met
the criterion for further splitting.
The analyses of the instrument’s reliability were gener-
ally supportive. However internal consistency of the
measure is often very restricted because many domains
only include a single item. This lack of sufficient num-
bers of items is an important limitation in the design of
the VFQ-25. It is better practice to have multiple items
per domain, for example, between four and ten items as
this provides a much more thorough assessment of the
dimension. The overall measurement properties of the
VFQ-25 (i.e. not just reliability) would be improved if
there were more items per domain, or perhaps fewer
domains.
The evidence to support concurrent and construct (dis-
criminant and convergent) validity was mixed. Significant
correlations were found between VFQ-25 and EQ-5D VAS
scores, but these were generally low. Regression analyses
found that different domains of the VFQ-25 were signifi-
cantly predicted by variables such as ECOG, HbA1c, and
ETDRS but this pattern of findings was not consistent. In-
deed it wasn’t clear to the authors what pattern of results
Table 3 Internal consistency reliability, concurrent validity, and construct validity at baseline
Internal-consistency
reliability



















N/A 0.43 0.19 0.10 41.0 ± 24.17 33.5 ± 22.07 .078
2. General
Vision
N/A 0.30 0.31 0.29 60.3 ± 15.27 46.4 ± 15.95 <.001
3. Ocular Pain 0.70 0.20 0.10 0.01 78.9 ± 23.67 76.1 ± 24.49 .52
4. Near
Activities
0.73 0.36 0.35 0.36 65.8 ± 21.93 45.1 ± 21.55 <.001
5. Distance
Activities
0.58 0.33 0.34 0.36 70.9 ± 23.44 51.2 ± 23.99 <.001
6. Social
Functioning
0.64 0.33 0.31 0.34 84.8 ± 19.51 69.1 ± 27.40 <.001
7. Mental
Health
0.78 0.35 0.33 0.30 65.3 ± 24.96 44.8 ± 27.62 <.001
8. Role
Difficulties
0.77 0.16 0.27 0.23 59.4 ± 30.67 44.1 ± 26.40 .004
9.
Dependency
0.85 0.37 0.34 0.34 78.0 ± 26.40 55.6 ± 33.39 <.001
10. Driving 0.75 0.34 0.41 0.51 65.5 ± 32.09 31.8 ± 33.52 <.001
11. Colour
Vision
N/A 0.19 0.18 0.14 87.7 ± 19.16 81.8 ± 24.49 .14
12. Peripheral
Vision
N/A 0.19 0.26 0.36 75.4 ± 25.83 61.4 ± 25.14 .003
VFQ-25
Composite
0.92 0.38 0.39 0.40 72.1 ± 17.91 56.1 ± 18.00 <.001
* Cronbach’s alpha is only applicable for multi-item scales.
Table 4 Results from stepwise multiple regression analysis of predictors of VFQ-25 domain scores
EQ-5D VAS HbA1C <7.6% ETDRS Duration of vision problems Age Gender ECOG
General health ** ** *
General vision ** **
Ocular pain **
Near activities ** **
Distance activities ** **
Social functioning ** **
Mental health ** * ** *
Role difficulties * ** * * *
Dependency ** * ** *
Driving ** * * *
Color vision **
Peripheral vision ** ** *
* = P < 0.05, ** = P < 0.01
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Table 5 Responsiveness from baseline to week 54
Group: Patients with a > = 5 letter improvement on the ETDRS in their study eye between baseline and week 54
VFQ-25 Change Score Guyatt’s Responsiveness
VFQ-25 Domain n Mean P value from one-sample t-test Effect Size* SRM† n Statistic‡
1. General Health 93 3.23 .14 0.15 0.15 30 0.12
2. General Vision 93 10.32 <.001 0.55 0.56 30 0.57
3. Ocular Pain 93 2.96 .16 0.13 0.15 30 0.14
4. Near Activities 93 5.69 .011 0.23 0.27 30 0.29
5. Distance Activities 93 3.67 .12 0.15 0.16 30 0.21
6. Social Functioning 93 0.54 .75 0.02 0.03 30 0.02
7. Mental Health 93 4.64 .024 0.17 0.24 30 0.21
8. Role Difficulties 93 11.29 <.001 0.41 0.38 30 0.49
9. Dependency 93 2.78 .25 0.09 0.12 30 0.10
10. Driving 56 5.73 .018 0.16 0.33 17 0.25
11. Colour Vision 91 1.92 .35 0.09 0.10 30 0.09
12. Peripheral Vision 93 4.30 .070 0.17 0.19 30 0.19
VFQ-25 Composite 93 4.90 <.001 0.26 0.43 30 0.39
* Effect size: the mean change score divided by the standard deviation of the baseline score.
† Standardized response mean: the mean change score divided by the standard deviation of the change score.
‡ Guyatt's responsiveness statistic: the mean change score divided by the standard deviation of change in subjects who remained stable. Stable groups are
defined as an increase or a decrease of up to 1 letter.
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based upon very similar patterns of correlations between
visual acuity and VFQ-25 in patients with diabetic retinop-
athy, Matza et al. [35] concluded that the instrument
“demonstrated construct validity”. The interpretation of
whether something is psychometrically valid is subjective
and reflects different points of view.
The analysis of known groups validity did demonstrate
that the measure could differentiate between patients
based on ETDRS letter score. However, the explorationTable 6 Minimal important difference from baseline to
week 54
VFQ-25 Domain N SEM* 1/2 SD
1. General Health 197 NA 10.95
2. General Vision 197 NA 8.80
3. Ocular Pain 197 11.98 10.53
4. Near Activities 197 9.17 10.24
5. Distance Activities 197 10.19 11.07
6. Social Functioning 197 9.64 9.87
7. Mental Health 197 10.21 10.56
8. Role Difficulties 197 14.04 14.40
9. Dependency 197 10.21 12.49
10. Driving 118 8.79 9.44
11. Colour Vision 194 NA 10.22
12. Peripheral Vision 196 NA 12.12
VFQ-25 Composite 197 3.33 6.13
* Standard deviation * √ (1- Cronbach's Alpha).of the validity of the VFQ-25 was rather complicated be-
cause of the wide conceptual scope of the instrument.
The VFQ-25 includes domains which reflect central vis-
ual function – such as near and distance activities, and
driving- domains which should be related to visual acu-
ity in DME patients. The instrument also includes more
general domains such as role difficulties and social func-
tioning which will be influenced by many factors other
than central vision. Therefore there are a priori reasons
as to why these domains would not be related to ETDRS
score. In reality, however, the association between do-
main scores and visual acuity was no greater for vision-
related domains than it was for the more general
domains. This indicates that much of what the VFQ-25
is measuring is not related to visual functioning. This ar-
gument is supported when the correlations with EQ-5D
VAS are considered.
Other authors have raised fundamental concerns regard-
ing the performance of the VFQ-25. Marella et al. [36] re-
port a study which employed Rasch analysis to explore the
performance of the VFQ-25 in patients with low vision
and concluded the 12 factor structure of the VFQ-12 has
no psychometric validity. They proposed a simpler two
factor solution reflecting visual and socio-emotional func-
tioning. Some of the items do not fit this structure and the
authors suggest that these be dropped (when the instru-
ment is used in patients with low vision). In addition the
Rasch analysis indicated that many of the items could ef-
fectively be reduced to a dichotomous outcome. This
study, and others [37,38], have also highlighted limitations
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and failings related to its psychometric performance;
nonetheless, it was able to measure various aspects of
HRQoL in patients with DME.
There are some important limitations with our study.
The analyses were undertaken retrospectively on clinical
trial data and, consequently, the data available for the
analyses were limited. Quite detailed ophthalmology data
were available but there were limited data from other
measures of HRQoL as might be expected in a clinical
trial, as trial participants may already be overburdened
with clinical measurements required by the protocol.
HRQoL was restricted to the EQ-5D, and for these ana-
lyses only the VAS was used. The VAS is an assessment
of general health status and as such was probably influ-
enced by many factors. It would be useful to gather
more detailed information perhaps using a generic pro-
file measure of HRQoL, and in addition an alternative
measure of vision-specific HRQoL. In our analyses of
construct validity we relied on the EQ-5D VAS to
benchmark the VFQ-25 data against. We believe this is a
limitation of our study because the EQ-5D VAS is a sin-
gle item scale which assesses self-rated health. Therefore,
while the EQ-5D VAS may be able to provide an over-
view of health status, it is not specific to the domains
that the VFQ-25 is measuring. This makes it difficult to
interpret the importance of correlations. It would have
been preferable to benchmark against another profile
measure. In addition, we used the EQ-5D VAS to bench-
mark MID of vision specific functioning and HRQoL.
While estimates of MID on these measures have been
previously reported, it should be remembered that the
EQ-5D VAS assesses overall health status. Therefore this
is not the most appropriate anchor to use for assessing
the MID of vision-specific functioning and HRQL as
measured by the VFQ-25. It would have been preferable
to use anchors that are much more specific to the do-
main being assessed, but such data were not captured in
the trial.
It should also be noted that because of the nature of
the condition, the data were collected using a validated
telephone interview script rather than through self-
report or face-to-face interviews, apart from in India
where telephone interviews were not possible. This ad-
ministration method was not specifically examined as a
predictor variable in the psychometric analyses.
The present study suggests that the VFQ-25 has some
validity as a measure of HRQoL in patients with DME.
It performs as well in DME as in assessment of diabetic
retinopathy [10], and age related macular degeneration
[39]. However, consistent with other studies, the VFQ-25
has some important limitations. To improve measure-
ment of vision-related quality of life in DME patients, a
new or modified instrument should be developed.Competing interests
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